Literature DB >> 21940387

Antithrombin prevents apoptosis by regulating inflammation in the liver in a model of cold ischemia/warm reperfusion injury.

Sevil Isik1, Pars Tuncyurek, Neslihan Inci Zengin, Ali Eba Demirbag, Fuat Atalay, Sezai Yilmaz, Taner Orug.   

Abstract

BACKGROUND/AIMS: Hepatic ischemia-reperfusion injury is a major problem in liver surgery. To modulate the complex process of inflammation, additional drugs to add to well-defined organ preserving solutions have been sought. The aim of the current study was to investigate the additive potential of antithrombin (AT) in liver preservation.
METHODOLOGY: Female Wistar rats were randomized into four groups: sham (Group I), experiment model (Group II), and treatment groups with AT (250U/kg) administration systematically (Group III) or locally (Group IV) before hepatectomy. UW solution was used for liver preservation for 24h at 4°C. The livers in group II, III and IV were reperfused 1h and histopathological parameters were evaluated microscopically. Apoptosis was assessed with TUNEL test.
RESULTS: Karyorrhexis was lower in the local treatment with AT group. Sinusoidal desquamation and mononuclear cell infiltration was higher in the experimental model group. Sinusoidal enlargement was higher in the systemic AT treatment group and neutrophil infiltration to sinusoids was lowest in the local treatment group. Apoptosis of hepatocytes and sinusoidal cells were significantly suppressed in rats that were treated with AT via portal vein infusion.
CONCLUSIONS: AT treatment obviously contributed to liver preservation in our model; the effects on apoptosis and inflammation were prominent. Therefore, AT should be considered as a potent agent although its clinical role has yet to be defined in ex-vivo hepatic preservation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21940387     DOI: 10.5754/hge11317

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  6 in total

1.  Antithrombin as a marker of severe acute hepatitis B.

Authors:  Simona Arientová; O Beran; P Chalupa; M Kořínková; M Holub
Journal:  Indian J Gastroenterol       Date:  2019-05-14

2.  Clinical Significance of Serum Antithrombin III Activity After Hepatectomy for Hepatocellular Carcinoma.

Authors:  Naruo Tokuyasu; Masataka Amisaki; Takehiko Hanaki; Yuki Murakami; Masaki Morimoto; Ei Uchinaka; Takuki Yagyu; Keisuke Goto; Tomoyuki Matsunaga; Manabu Yamamoto; Shuichi Takano; Teruhisa Sakamoto; Soichiro Honjo; Toshimichi Hasegawa; Yoshiyuki Fujiwara
Journal:  Yonago Acta Med       Date:  2021-04-15       Impact factor: 1.641

3.  Biomarkers of systemic inflammation in farmers with musculoskeletal disorders; a plasma proteomic study.

Authors:  Bijar Ghafouri; Anders Carlsson; Sara Holmberg; Anders Thelin; Christer Tagesson
Journal:  BMC Musculoskelet Disord       Date:  2016-05-10       Impact factor: 2.362

4.  Early prediction of postoperative liver dysfunction and clinical outcome using antithrombin III-activity.

Authors:  David Pereyra; Florian Offensperger; Florian Klinglmueller; Stefanie Haegele; Lukas Oehlberger; Thomas Gruenberger; Christine Brostjan; Patrick Starlinger
Journal:  PLoS One       Date:  2017-04-13       Impact factor: 3.240

5.  Antithrombin supplementation during extracorporeal membrane oxygenation: study protocol for a pilot randomized clinical trial.

Authors:  Mauro Panigada; Elena Spinelli; Alberto Cucino; Elisa Cipriani; Stefano De Falco; Giovanna Panarello; Giovanna Occhipinti; Antonio Arcadipane; Gabriele Sales; Vito Fanelli; Luca Brazzi; Cristina Novembrino; Dario Consonni; Antonio Pesenti; Giacomo Grasselli
Journal:  Trials       Date:  2019-06-11       Impact factor: 2.279

6.  The relationship between antithrombin administration and inflammation during veno-venous ECMO.

Authors:  Mauro Panigada; Elena Spinelli; Stefano De Falco; Dario Consonni; Cristina Novembrino; Massimo Boscolo Anzoletti; Giovanna Panarello; Giovanna Occhipinti; Claudia C Dos Santos; Antonio Pesenti; Antonio Arcadipane; Giacomo Grasselli
Journal:  Sci Rep       Date:  2022-08-22       Impact factor: 4.996

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.